Skip to main content
. 2016 Sep 19;84(10):3083–3091. doi: 10.1128/IAI.00639-16

FIG 2.

FIG 2

Characterization of ST-induced GUCYC2 activation and cGMP production. (A and B) cGMP production was shown in medium samples of ST-induced Gucy2c+/+ mouse enteroids (A), linaclotide-induced Gucy2c+/+ mouse enteroids (A), and healthy human enteroids (B) preincubated for 1 h with IBMX (1 mM) and stimulated with either TJU (control), ST (10 μM), or linaclotide (10 μM) for 24 h. (C) The loss of cGMP production was shown in medium samples from Gucyc−/− mouse enteroids preincubated for 1 h with IBMX (1 mM) and stimulated with either TJU (control) or linaclotide (10 μM) for 24 h. (D) GUCY2C activation was shown by immunoblot analysis of p-VASP Ser239 and GAPDH (loading control) in Gucy2c+/+ mouse enteroids treated with TJU (control) or linaclotide (1 μM) and in Gucy2c−/− mouse enteroids treated with TJU (untreated), linaclotide (1 μM), or 8-Br-cGMP (10 μM) for 24 h (results are means ± SEM). (E) Immunoblot analysis results for p-VASP Ser239 and GAPDH (loading control) in healthy human enteroids treated with TJU (control) or linaclotide (10 μM) for 24 h (results are means ± SEM). **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.